ストックスクリーナーアプリを入手
4.59
8.20%
-0.41
アフターアワーズ：
4.58
-0.010
-0.22%
前日終値:
$5.00
開ける：
$5
24時間の取引高:
103.21K
Relative Volume:
0.55
時価総額：
$249.73M
収益：
-
当期純損益:
$-238.77M
株価収益率:
-0.1712
EPS:
-26.808
ネットキャッシュフロー:
$-216.62M
1週間 パフォーマンス:
-10.00%
1か月 パフォーマンス:
-10.00%
6か月 パフォーマンス:
-60.40%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.57
$5.01
1週間の範囲:
$4.534
$5.05
52週間の値動き範囲:
$4.36
$13.50
Alumis Inc Stock (ALMS) Company Profile
ALMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.59 | 249.73M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | 開始されました | Oppenheimer | Outperform |
| 2024-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 開始されました | Guggenheim | Buy |
| 2024-07-23 | 開始されました | Leerink Partners | Outperform |
| 2024-07-23 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Alumis Inc (ALMS) 最新ニュース
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - San Francisco Business Times
Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGR - GlobeNewswire Inc.
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - EIN News
Alumis (NASDAQ:ALMS) Receives Buy Rating from HC Wainwright - Defense World
How a skin drug trial could help Peninsula biotech pull off key merger - The Business Journals
H.C. Wainwright maintains Alumis stock Buy rating, $19 target By Investing.com - Investing.com South Africa
Alumis to Present at Leerink's 2025 Global Healthcare Conference - StockTitan
Promising Efficacy of Alumis Inc.’s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy Rating - TipRanks
Alumis announces data from the OLE of its Phase 2 STRIDE trial - TipRanks
Alumis Says Phase 3 Onward Program Ongoing With Topline Data Expected In Q1 2026 - Marketscreener.com
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis - The Manila Times
New Psoriasis Drug Maintains Remarkable 61% Skin Clearance After One YearKey Trial Results - StockTitan
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
Acelyrin falls as Acelyrin reaffirms deal commitment - MSN
Acelyrin rebuffs Concentra bid, believing Alumis option better - The Pharma Letter
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger - BioSpace
Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating - TipRanks
Acelyrin To Proceed With Alumis Merger, Spurn Concentra Bid - Citeline News & Insights
Sector Update: Health Care Stocks Lower Tuesday Afternoon -March 04, 2025 at 02:01 pm EST - Marketscreener.com
Acelyrin Reaffirms Merger Deal With Alumis -March 04, 2025 at 10:13 am EST - Marketscreener.com
Acelyrin stock falls on Acelyrin deal commitment (SLRN:NASDAQ) - Seeking Alpha
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - The Manila Times
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis Inc. and ACELYRIN, Inc. Confirm Commitment to All-Stock Merger to Create Leading Biopharma Company in Immune-Mediated Diseases - Nasdaq
Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger -March 04, 2025 at 09:06 am EST - Marketscreener.com
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not ... - Eagle-Tribune
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment? - StockTitan
Acelyrin stock down after reaffirming Alumis deal (SLRN:NASDAQ) - Seeking Alpha
Alumis (NASDAQ:ALMS) Given “Buy” Rating at HC Wainwright - Defense World
Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target - TipRanks
Alumis presents new psoriasis drug data, eyes Phase 3 results in 2026 - Investing.com Australia
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout - The Manila Times
Alumis presents new psoriasis drug data, eyes Phase 3 results in 2026 By Investing.com - Investing.com South Africa
Can Alumis's Fast-Tracked Psoriasis Drug Challenge Market Leaders? Phase 3 Timeline Speeds Up - StockTitan
Alumis to present new data on multiple sclerosis therapy By Investing.com - Investing.com South Africa
Alumis to present new data on multiple sclerosis therapy - Investing.com
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases - The Manila Times
Can Alumis' Brain-Penetrating Drug Transform Multiple Sclerosis Treatment? Phase 1 Results Suggest Yes - StockTitan
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report - BioCentury
When (ALMS) Moves Investors should Listen - Stock Traders Daily
Alumis Inc. introduces severance and change in control plan By Investing.com - Investing.com Canada
Alumis Inc. Approves New Severance and Control Plan - TipRanks
Activist investor threatens drug maker's merger plans with L.A. biotech - The Business Journals
Alumis Inc. introduces severance and change in control plan - Investing.com India
Activist investor threatens Peninsula drug maker's merger plansSan Francisco Business Times - The Business Journals
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - The Manila Times
Alumis (ALMS) to Release Earnings on Wednesday - MarketBeat
Acelyrin, Inc. Confirms Unsolicited Acquisition Proposal from Concentra Biosciences Amidst Ongoing Merger Agreement with Alumis Inc. - Nasdaq
Can This New Cash Offer Derail ACELYRIN's Planned Alumis Merger? - StockTitan
Alumis Inc (ALMS) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):